These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22450873)

  • 1. Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.
    Aregbe AO; Sherer EA; Egorin MJ; Scher HI; Solit DB; Ramanathan RK; Ramalingam S; Belani CP; Ivy PS; Bies RR
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):201-5. PubMed ID: 22450873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
    Kummar S; Gutierrez ME; Gardner ER; Chen X; Figg WD; Zajac-Kaye M; Chen M; Steinberg SM; Muir CA; Yancey MA; Horneffer YR; Juwara L; Melillo G; Ivy SP; Merino M; Neckers L; Steeg PS; Conley BA; Giaccone G; Doroshow JH; Murgo AJ
    Eur J Cancer; 2010 Jan; 46(2):340-7. PubMed ID: 19945858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
    Glaze ER; Lambert AL; Smith AC; Page JG; Johnson WD; McCormick DL; Brown AP; Levine BS; Covey JM; Egorin MJ; Eiseman JL; Holleran JL; Sausville EA; Tomaszewski JE
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):637-47. PubMed ID: 15986212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
    Pacey S; Wilson RH; Walton M; Eatock MM; Hardcastle A; Zetterlund A; Arkenau HT; Moreno-Farre J; Banerji U; Roels B; Peachey H; Aherne W; de Bono JS; Raynaud F; Workman P; Judson I
    Clin Cancer Res; 2011 Mar; 17(6):1561-70. PubMed ID: 21278242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin.
    Furth AF; Mandrekar SJ; Tan AD; Rau A; Felten SJ; Ames MM; Adjei AA; Erlichman C; Reid JM
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):39-45. PubMed ID: 17909811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.
    Ramanathan RK; Egorin MJ; Erlichman C; Remick SC; Ramalingam SS; Naret C; Holleran JL; TenEyck CJ; Ivy SP; Belani CP
    J Clin Oncol; 2010 Mar; 28(9):1520-6. PubMed ID: 20177028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.
    Zheng N; Zou P; Wang S; Sun D
    Drug Metab Dispos; 2011 Apr; 39(4):627-35. PubMed ID: 21177985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
    Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI
    Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL; Floret S; Bentzen C
    Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
    Robles AI; Wright MH; Gandhi B; Feis SS; Hanigan CL; Wiestner A; Varticovski L
    Clin Cancer Res; 2006 Nov; 12(21):6547-56. PubMed ID: 17085670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
    Bull EE; Dote H; Brady KJ; Burgan WE; Carter DJ; Cerra MA; Oswald KA; Hollingshead MG; Camphausen K; Tofilon PJ
    Clin Cancer Res; 2004 Dec; 10(23):8077-84. PubMed ID: 15585643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
    Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
    Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
    Ramalingam SS; Egorin MJ; Ramanathan RK; Remick SC; Sikorski RP; Lagattuta TF; Chatta GS; Friedland DM; Stoller RG; Potter DM; Ivy SP; Belani CP
    Clin Cancer Res; 2008 Jun; 14(11):3456-61. PubMed ID: 18519777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17-DMAG inhibits the multiplication of several Babesia species and Theileria equi on in vitro cultures, and Babesia microti in mice.
    Guswanto A; Nugraha AB; Tuvshintulga B; Tayebwa DS; Rizk MA; Batiha GE; Gantuya S; Sivakumar T; Yokoyama N; Igarashi I
    Int J Parasitol Drugs Drug Resist; 2018 Apr; 8(1):104-111. PubMed ID: 29499568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
    Weigel BJ; Blaney SM; Reid JM; Safgren SL; Bagatell R; Kersey J; Neglia JP; Ivy SP; Ingle AM; Whitesell L; Gilbertson RJ; Krailo M; Ames M; Adamson PC
    Clin Cancer Res; 2007 Mar; 13(6):1789-93. PubMed ID: 17363534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Maddocks K; Hertlein E; Chen TL; Wagner AJ; Ling Y; Flynn J; Phelps M; Johnson AJ; Byrd JC; Jones JA
    Leuk Lymphoma; 2016 Sep; 57(9):2212-5. PubMed ID: 26764527
    [No Abstract]   [Full Text] [Related]  

  • 19. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.
    Néant N; Gattacceca F; Lê MP; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Solas C
    Eur J Clin Pharmacol; 2018 Apr; 74(4):473-481. PubMed ID: 29374296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
    Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.